Based on these findings, in the current study we anticipate that increasing the expression of hsa-miR-223 could upregulate the expression of ABCA1 while inhibiting the expression of UGCG, thereby increasing cholesterol efflux, thus sensitizing ER+ breast cancer resistant cells or TNBC cells to chemotherapeutic agents. This evidence concerns the gene ABCA1 and breast cancer.